<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Immunol Immunother</journal-id><journal-title>Cancer Immunology, Immunotherapy </journal-title><issn pub-type="ppub">0340-7004</issn><issn pub-type="epub">1432-0851</issn><publisher><publisher-name>Springer-Verlag</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">17597332</article-id><article-id pub-id-type="pmc">1914259</article-id><article-id pub-id-type="publisher-id">295</article-id><article-id pub-id-type="doi">10.1007/s00262-007-0295-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>No evidence for circulating HuD-specific CD8<sup>+</sup> T cells in patients with paraneoplastic neurological syndromes and Hu antibodies</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>de Beukelaar</surname><given-names>Janet W.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Verjans</surname><given-names>Georges M.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>van Norden</surname><given-names>Yvette</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Milikan</surname><given-names>Johannes C.</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kraan</surname><given-names>Jaco</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hooijkaas</surname><given-names>Herbert</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sintnicolaas</surname><given-names>Kees</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Gratama</surname><given-names>Jan W.</given-names></name><address><phone>+31-10-4391418</phone><fax>+31-10-4391005</fax><email>j.w.gratama@erasmusmc.nl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sillevis Smitt</surname><given-names>Peter A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Medical Oncology, Room E-2-80B, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands </aff><aff id="Aff2"><label>2</label>Department of Neurology, Erasmus University Medical Center, &#x02019;s Gravendijkwal, 230 3015 CE Rotterdam, The Netherlands </aff><aff id="Aff3"><label>3</label>Department of Virology, Erasmus University Medical Center, &#x02019;s Gravendijkwal, 230 3015 CE Rotterdam, The Netherlands </aff><aff id="Aff4"><label>4</label>Department of Trials and Statistics, Erasmus University Medical Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands </aff><aff id="Aff5"><label>5</label>Department of Immunology, Erasmus University Medical Center, &#x02019;s Gravendijkwal, 230 3015 CE Rotterdam, The Netherlands </aff><aff id="Aff6"><label>6</label>Laboratory for Histocompatibility and Immunogenetics, Sanquin Blood Bank South West Region, Rotterdam, The Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>14</day><month>2</month><year>2007</year></pub-date><pub-date pub-type="ppub"><month>9</month><year>2007</year></pub-date><volume>56</volume><issue>9</issue><fpage>1501</fpage><lpage>1506</lpage><history><date date-type="received"><day>16</day><month>11</month><year>2006</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2007</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag 2007</copyright-statement></permissions><abstract><sec><title>Aim</title><p>In paraneoplastic neurological syndromes (PNS) associated with small cell lung cancer (SCLC) and Hu antibodies (Hu-PNS), Hu antigens expressed by the tumour hypothetically trigger an immune response that also reacts with Hu antigens in the nervous system, resulting in tumour suppression and neuronal damage. To gain more insight into the hypothesized CD8<sup>+ </sup>T cell-mediated immune pathogenesis of these syndromes, we searched for circulating HuD-specific CD8<sup>+</sup> T cells in a large cohort of Hu-PNS patients and controls.</p></sec><sec><title>Patients and methods</title><p>Blood was tested from 43 Hu-PNS patients, 31 Hu antibody negative SCLC patients without PNS and 54 healthy controls. Peripheral blood mononuclear cells (PBMC) were stimulated with HuD protein-spanning peptide pools (15-mers) and individual HuD-derived peptides (9-mers) and analysed by cytokine flow cytometry and interferon-&#x003b3; ELISPOT-assays. Additionally, HuD-based Class I HLA multimers were used to visualize HuD-specific CD8<sup>+</sup> T cells.</p></sec><sec><title>Results</title><p>No HuD-specific CD8<sup>+ </sup>T cells could be detected in the blood of Hu-PNS patients or controls.</p></sec><sec><title>Conclusions</title><p>Our results do not support a role for HuD-specific CD8<sup>+</sup> T cells in Hu-PNS. Further studies should focus on the detection of circulating HuD-specific CD4<sup>+ </sup>T cells and examine the antigen specificity of T cells in affected tissues.</p></sec></abstract><kwd-group><title>Keywords</title><kwd>Paraneoplastic</kwd><kwd>Anti-tumour immunity</kwd><kwd>T lymphocyte</kwd><kwd>SCLC</kwd><kwd>HuD</kwd><kwd>HLA class I multimer</kwd></kwd-group><custom-meta-wrap><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag 2007</meta-value></custom-meta></custom-meta-wrap></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction </title><p>Paraneoplastic neurological syndromes (PNS) are considered as naturally occurring, successful anti-tumour immune responses in humans [<xref ref-type="bibr" rid="CR6">6</xref>]. However, this tumour immunity goes along with autoaggression against the nervous system, resulting in severe neurological dysfunction [<xref ref-type="bibr" rid="CR9">9</xref>]. The mechanisms responsible for the anti-tumour response and neuronal damage are poorly understood. Antigens expressed by the tumour that are normally restricted to neurons (so-called onconeuronal antigens) hypothetically trigger an immune response that cross-reacts with the same antigens in the nervous system [<xref ref-type="bibr" rid="CR7">7</xref>]. One of the most frequently involved tumours is small cell lung cancer (SCLC) and approximately 50% of patients with PNS and SCLC have high-titre Hu antibodies (Hu-PNS). Hu antibodies are directed against a family of neuron specific, mRNA binding proteins, of which HuD is the best-documented member. Consistent expression of HuD in all SCLC suggests that HuD plays a central role in triggering the immune response [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>High titres of Hu antibodies in serum and cerebrospinal fluid suggested a pathogenic role for these antibodies, that could, however, never be proven in animal models [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Furthermore, expression of Hu antigens is exclusively intracellular, and it is therefore difficult to understand how such antibodies could target tumours or neurons [<xref ref-type="bibr" rid="CR5">5</xref>]. In addition, pathological examination of PNS neuronal tissue demonstrated localized inflammatory cell infiltrates, containing B cells, CD4<sup>+</sup> and CD8<sup>+</sup> T cells, in the proximity of overt neuronal cell damage [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. The presence of an oligoclonal CD8<sup>+</sup> T cell infiltrate in nervous tissues and tumours of Hu-PNS patients further suggests an immunopathogenic role for such cells [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR25">25</xref>].</p><p>Some authors report the presence of HuD peptide-specific CD8<sup>+</sup> T cells in the blood of these patients, but also in that of apparently healthy controls (HC) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In addition, the presence of circulating HuD-specific CD4<sup>+</sup> T cells has been suggested [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Here, we have investigated the presence of circulating HuD-specific T cells in a large cohort of Hu-PNS patients and controls. Despite a multifaceted approach mainly geared towards the detection of HuD-reactive CD8<sup>+</sup> T cells and, to a somewhat lesser extent, CD4<sup>+</sup> T cells, no such cells were detected in the blood of Hu-PNS patients and controls.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and methods</title><sec id="Sec3"><title>Patients</title><p>Forty-three patients with high-titred Hu antibodies and a definite clinical diagnosis of PNS [<xref ref-type="bibr" rid="CR12">12</xref>], 31 Hu antibody negative SCLC patients without neurological symptoms or signs (SCLC) and 54 apparently HC were tested. The Erasmus MC Institutional Review Board approved the study and all individuals provided written informed consent. The individuals&#x02019; class I HLA alleles were typed by standard diagnostic PCR at the two-digit resolution level. Patient characteristics are shown in the Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Anti-Hu IgG titres were determined as described previously [<xref ref-type="bibr" rid="CR21">21</xref>] and in Hu-PNS the dependence in activities of daily living was scored using the modified Rankin scale [<xref ref-type="bibr" rid="CR21">21</xref>]. Twenty-five HC were male and 29 female, their median age was 46&#x000a0;years (range 17&#x02013;89) and all were Hu antibody negative. No HC had received previous chemotherapy or immunosuppressive treatment and 30 HC (56%) were CMV-seropositive.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Patient characteristics at the time of study entry</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Hu-PNS </th><th align="left">SCLC </th></tr></thead><tbody><tr><td align="left">N</td><td align="left">43</td><td align="left">31</td></tr><tr><td align="left">Age (median, range)</td><td align="left">64 (4&#x02013;81)<sup>a</sup></td><td align="left">61 (40&#x02013;83)</td></tr><tr><td align="left">Gender (M/F)</td><td align="left">15/28</td><td align="left">21/10</td></tr><tr><td align="left">Hu-Ab titre (median, range)</td><td align="left">12,800 (400&#x02013;204,800)</td><td align="left">Negative</td></tr><tr><td align="left">CMV serostatus (pos/neg)</td><td align="left">29/14</td><td align="left">17/14</td></tr><tr><td align="left">Paraneoplastic neurological syndrome</td><td align="left"/><td align="left">NA</td></tr><tr><td align="left">&#x000a0;PSN</td><td align="left">27</td><td align="left"/></tr><tr><td align="left">&#x000a0;PEM</td><td align="left">5</td><td align="left"/></tr><tr><td align="left">&#x000a0;PCD</td><td align="left">4</td><td align="left"/></tr><tr><td align="left">&#x000a0;PLE/ BE</td><td align="left">3</td><td align="left"/></tr><tr><td align="left">&#x000a0;Pseudo-obstruction</td><td align="left">2</td><td align="left"/></tr><tr><td align="left">&#x000a0;Motor neuron disease</td><td align="left">2</td><td align="left"/></tr><tr><td align="left" colspan="3">Tumour</td></tr><tr><td align="left">&#x000a0;No tumour</td><td align="left">8<sup>b</sup></td><td align="left">0</td></tr><tr><td align="left">&#x000a0;SCLC</td><td align="left">31</td><td align="left">31</td></tr><tr><td align="left">&#x000a0;&#x000a0;Limited</td><td align="left">28</td><td align="left">17</td></tr><tr><td align="left">&#x000a0;&#x000a0;Extended</td><td align="left">3</td><td align="left">14</td></tr><tr><td align="left">&#x000a0;NSCLC</td><td align="left">2</td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Prostate</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left">&#x000a0;Neuroblastoma</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left" colspan="3">Prior treatment</td></tr><tr><td align="left">&#x000a0;None</td><td align="left">27</td><td align="left">27</td></tr><tr><td align="left">&#x000a0;Chemotherapy&#x000a0;&#x000b1;&#x000a0;immunosuppression</td><td align="left">16</td><td align="left">4</td></tr><tr><td align="left">Neurological symptoms</td><td align="left"/><td align="left">NA</td></tr><tr><td align="left">&#x000a0;Interval onset symptoms (study entry)</td><td align="left">5&#x000a0;months (2&#x02013;15)<sup>c</sup></td><td align="left"/></tr><tr><td align="left">&#x000a0;Interval onset symptoms (diagnosis)</td><td align="left">4&#x000a0;months (1&#x02013;12)<sup>c</sup></td><td align="left"/></tr><tr><td align="left">&#x000a0;Progressive at study entry<sup>d</sup></td><td align="left">34 (79%)</td><td align="left"/></tr><tr><td align="left">Modified Rankin score</td><td align="left"/><td align="left">NA</td></tr><tr><td align="left">&#x000a0;MRS&#x000a0;=&#x000a0;2</td><td align="left">7</td><td align="left"/></tr><tr><td align="left">&#x000a0;MRS&#x000a0;=&#x000a0;3</td><td align="left">22</td><td align="left"/></tr><tr><td align="left">&#x000a0;MRS&#x000a0;=&#x000a0;4</td><td align="left">10</td><td align="left"/></tr><tr><td align="left">&#x000a0;MRS&#x000a0;=&#x000a0;5</td><td align="left">4</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>Hu-Ab</italic> Hu antibody, <italic>CMV</italic> cytomegalovirus, <italic>pos</italic> positive, <italic>neg</italic> negative, <italic>NA</italic> not applicable, <italic>PSN</italic> paraneoplastic sensory neuronopathy, <italic>PEM</italic> paraneoplastic encephalomyelitis, <italic>PCD</italic> paraneoplastic cerebellar degeneration, <italic>PLE</italic> paraneoplastic limbic encephalitis, <italic>BE</italic> brainstem encephalitis, <italic>SCLC</italic> small cell lung cancer, <italic>NSCLC</italic> non-small cell lung cancer, <italic>MRS</italic> modified Rankin score</p><p><sup>a </sup>One Hu-PNS patient was a 4-year-old boy with an underlying neuroblastoma. The remaining Hu-PNS patients were aged between 49 and 81&#x000a0;years</p><p><sup>b </sup>No tumour mass visible on CT-scan or FDG-PET scan</p><p><sup>c </sup>Median (ranges) of intervals are shown</p><p><sup>d </sup>Progression of neurological symptoms was defined by the increase of at least one point on the modified Rankin scale during 2&#x000a0;months prior to study entry</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec4"><title>Reagents</title><p>Ninety-three HuD protein-spanning synthetic peptides, 15-mers with 11 amino acids overlap, were pooled to constitute the HuD peptide mix (HuDmix) and smaller peptide pools [Jerini Peptide Technologies (JPT), Berlin, Germany]. For interferon-&#x003b3; enzyme-linked immunosorbent spot-forming (IFN-&#x003b3; ELISPOT) assays and the construction of HLA class-I multimers, HuD-derived 9- and 10-mers were selected based on previous studies [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. The phycoerythrin (PE)-labeled multimers and corresponding peptides used were: HLA-A*0101-<sup>147</sup>ELEQLFSQY<sup>155</sup>, HLA-A*0101-<sup>245</sup>RLDNLLNMAY<sup>254</sup>, HLA-A*0201-<sup>86</sup>SLGYGFVNYI<sup>95</sup>, HLA-A*0201-<sup>248</sup>NLLNMAYGV<sup>256</sup>, HLA-A*0201-<sup>315</sup>QLFGPFGAV<sup>323</sup>, HLA-A*0201-<sup>362</sup>RLGDRVLQV<sup>370</sup>, and HLA-A*2402-<sup>154</sup>QYGRIITSRI<sup>163</sup> (ProImmune, Oxford, UK). As positive and negative controls, HLA-A*0201-<sup>495</sup>NLVPMVATV<sup>503</sup> [CMV phosphoprotein-65 (CMV-pp65); Beckman Coulter, San Diego, CA] and HLA-A*0201 presenting an irrelevant peptide (ProImmune), respectively, were included.</p><p>To measure general T-cell responsiveness, we used phorbol myristate acetate (PMA) plus ionomycin, or phytohemagglutinin (PHA). A peptide pool containing 15-mers spanning CMV-pp65 (JPT) was used as positive- and negative antigen-specific control in CMV seropositive and seronegative individuals, respectively.</p></sec><sec id="Sec5"><title>Cytokine flow cytometry</title><p>Peripheral blood mononuclear cells (PBMC) were isolated within 12&#x000a0;h after venipuncture and stimulated in duplicate as described elsewhere [<xref ref-type="bibr" rid="CR14">14</xref>]. Briefly, 2&#x000a0;&#x000d7;&#x000a0;10<sup>6</sup> PBMC were incubated at 37&#x000b0;C in a CO<sub>2</sub> incubator for 18&#x000a0;h with 1&#x000a0;&#x003bc;g/ml HuDmix, 1&#x000a0;&#x003bc;g/ml CMV-pp65, 1&#x000a0;&#x003bc;g/ml ionomycin plus 25&#x000a0;ng/ml PMA, or without antigen. After 2&#x000a0;h of stimulation, brefeldin A was added to one of the duplicate tubes allowing for intracellular accumulation of cytokines in activated T cells. Brefeldin A was not added to the second tube to allow detection of secreted cytokines in the supernatant. In some individuals, additional stimulation was performed in the presence of co-stimulatory monoclonal antibodies (mAb) directed against CD28 and CD49d (BD Biosciences, San Jose, CA). Stimulated PBMC were stained and analysed using anti-CD3 conjugated with peridinyl chlorophyllin (PerCP), anti-CD8 conjugated with allophycocyanin (APC), anti-interferon (IFN)-&#x003b3; conjugated with fluorescein isothiocyanate (FITC), anti-tumour necrosis factor (TNF)-&#x003b1; conjugated with PE, or appropriate isotype control mAb (all from BD Biosciences) [<xref ref-type="bibr" rid="CR14">14</xref>]. CD4<sup>+</sup> T cells were defined as CD3<sup>+</sup>, 8<sup>&#x02212;</sup>. Positive responses were defined by (1) percentage of cytokine-positive CD4<sup>+</sup> or CD8<sup>+</sup> T cells &#x0003e;2 times the negative control (i.e., no antigen) and (2) &#x02265;0.1% of the total number of CD4<sup>+</sup> or CD8<sup>+</sup> T cells, each after subtraction of isotype control results.</p></sec><sec id="Sec6"><title>Detection of secreted cytokines</title><p>The secretion levels of IFN-&#x003b3;, TNF-&#x003b1;, interleukin (IL)-2, IL-4, IL-5 and IL-10 were measured in supernatants using a cytometric bead array (BD Biosciences). Based on CMV data (not shown), a positive result was defined as cytokine concentration &#x0003e;2 times the background (no antigen) and a minimum level of 50&#x000a0;pg/ml.</p></sec><sec id="Sec7"><title>IFN-&#x003b3; ELISPOT</title><p>PBMC (2&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup>/well) were pre-stimulated in duplicate in 96-well plates with culture medium containing 3&#x000a0;&#x003bc;g/ml HuD 9-mers, HuDmix, CMV-pp65, PHA, or no antigen for 1.5&#x000a0;h at 37&#x000b0;C and 5% CO<sub>2</sub> [<xref ref-type="bibr" rid="CR10">10</xref>]. The PBMC were subsequently transferred to anti-IFN-&#x003b3;-coated ELISPOT plates (Nalge Nunc, Rochester, NY) for a further 18-h incubation. The ELISPOT assay was performed using standard protocols and automated reading (AELVIS GmbH, Hanover, Germany) [<xref ref-type="bibr" rid="CR10">10</xref>]. The mean number of spot-forming cells (SFC) in duplicate wells was used as assay outcome. Positive results were defined by numbers of SFC/well &#x0003e;3 times background (no antigen) and a minimum of 15 SFC/well.</p></sec><sec id="Sec8"><title>Detection of HuD-specific CD8<sup>+</sup> T cells using Class-I HLA multimers</title><p>Thawed PBMC were stained as described previously [<xref ref-type="bibr" rid="CR11">11</xref>]. Following acquisition of 1&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> viable (i.e., 7-amino-actinomycin-D [7AAD] negative) CD8<sup>+</sup> T cells, a positive result required a percentage of &#x02265;0.1% of viable CD8<sup>+</sup> T cells binding the HuD multimer and a brightly staining HuD multimer-binding CD8<sup>+</sup> T-cell population that did not overlap with the dimly staining irrelevant multimer-binding T-cell population.</p></sec></sec><sec id="Sec9" sec-type="results"><title>Results</title><sec id="Sec10"><title>Cytokine flow cytometry of PBMC after stimulation with HuD-derived peptides</title><p>Stimulation with PMA and ionomycin induced IFN-&#x003b3; production in both CD4<sup>+</sup> and CD8<sup>+</sup> T cells of all individuals (not shown). Whilst all CMV-seropositive individuals specifically responded to CMV-pp65, no HuD-specific T-cell reactivity was observed in any of the Hu-PNS patients, SCLC patients or HC (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a, b). Similar results were obtained when intracellular TNF-&#x003b1; (not shown) or secreted cytokines (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>c) were measured. The use of co-stimulatory antibodies in combination with HuDmix did not result in the detection of HuD-specific T-cell reactivity (not shown).
<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>Cytokine production in response to HuDmix and HLA-matched HuD 9-mers. Proportions of CD8<sup>+</sup> (<italic>panel a</italic>) and CD4<sup>+</sup> (<italic>panel b</italic>) T cells expressing intracellular IFN-&#x003b3; after stimulation with HuDmix in Hu-PNS patients, SCLC and healthy controls. Each dot represents the result observed in a single individual (<italic>panel c</italic>). After stimulation of PBMC with HuDmix and control antigens, the indicated cytokines were measured in assay supernatants. The results are shown for Hu-PNS patients only. <italic>Horizontal lines</italic> indicate median values of each group (<italic>panel d</italic>). ELISPOT assay showing the number of IFN-&#x003b3; SFC after stimulation of 2&#x000a0;&#x000d7;&#x000a0;10<sup>5</sup> PBMC with HuDmix or HuD 9-mers. Each dot represents the mean result of duplicates for each stimulus in each individual (<italic>panels a&#x02013;d</italic>). Responses to CMV antigens are shown for CMV seropositive individuals only, as they were consistently negative in CMV seronegative individuals (not shown). The numbers of individuals tested are given in between brackets. <italic>NEG</italic> negative control (incubation without antigen), <italic>HuDmix</italic> HuD protein-spanning peptide pool, <italic>PP65</italic> CMV pp-65 protein-spanning peptide pool, <italic>IL</italic> interleukin <italic>TNF</italic> tumour necrosis factor, <italic>IFN</italic> interferon, <italic>SFC</italic> spot-forming cell, <italic>PHA</italic> phytohemagglutinin.<italic> ELE</italic>,<italic> RLD</italic>,<italic> SLG</italic>,<italic> NLL</italic>,<italic> QLF</italic>,<italic> RLG</italic> and<italic> QYG</italic> designate individual HuD-based peptides</p></caption><graphic position="anchor" xlink:href="262_2007_295_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec11"><title>IFN&#x003b3;-ELISPOT assay on PBMC stimulated with HuD-derived 9-mers</title><p>All individuals responded to PHA as determined by IFN&#x003b3;-ELISPOT assay. In addition, all CMV-seropositive individuals responded to CMV-pp65. However, no T cell reactivity towards the previously described class-I HLA-binding HuD peptides [<xref ref-type="bibr" rid="CR20">20</xref>] was detected in individuals with the appropriate HLA types in any of the study groups (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>d).</p></sec><sec id="Sec12"><title>Analysis of HuD-specific CD8<sup>+</sup> T cells using Class-I HLA multimers</title><p>Finally, we investigated the presence of HuD-specific CD8<sup>+</sup> T cells in PBMC using Class-I HLA multimers containing HuD-derived peptides. Whilst CMV-seropositive individuals with the appropriate HLA types showed distinct populations of pp65 multimer-binding CD8<sup>+ </sup>T cells, no HuD-specific CD8<sup>+</sup> T cells were observed in individuals with the appropriate HLA types in any of the study groups (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).
<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>Analysis of HuD peptide-loaded, Class-I HLA multimer-binding CD8<sup>+</sup> T cells. PBMC from a CMV-seropositive Hu-PNS patient were stained with HLA-A*0201&#x000a0;multimers loaded with the HuD peptide SLGYGFVNYI (<italic>panel a</italic>), an irrelevant peptide (<italic>panel b</italic>) or with the CMV-pp65 peptide NLVPMVATV (<italic>panel c</italic>). All data shown are obtained after selection of T cells (i.e., CD3<sup>+</sup>, low sideward scatter signals) [<xref ref-type="bibr" rid="CR12">12</xref>]. Binding of Class-I HLA multimers (<italic>panels a&#x02013;c</italic>, <italic>horizontal axes</italic>) was analysed in relation to CD8 expression. In this example, the proportion of SLGYGFVNYI multimer-binding CD8<sup>+</sup> T cells (0.36%) was similar to that of irrelevant multimer-binding CD8<sup>+</sup> T cells (0.46%); binding resulted in low-intensity fluorescence signals only. In contrast, 2.46% of CD8<sup>+</sup> T cells bound the NLVPMVATV multimer resulting in high-intensity fluorescence signals from most CD8<sup>+</sup> T cells</p></caption><graphic position="anchor" xlink:href="262_2007_295_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p>We set out to detect HuD-specific T cells in the blood of Hu-PNS patients as they are postulated to play a pivotal role in the immunopathology of this disease. Although we applied three different approaches we could not detect circulating HuD-specific T cells.</p><p>First, to induce cytokine responses in T cells, we used 15-mer protein-spanning peptide pools that have the advantage of covering the full protein sequence and of eliciting both CD8<sup>+</sup> and CD4<sup>+</sup> T-cell responses [<xref ref-type="bibr" rid="CR14">14</xref>], as demonstrated by the CD8<sup>+ </sup>and CD4<sup>+</sup> CMV-pp65-specific T-cell responses. However, no CD8<sup>+</sup> or CD4<sup>+</sup> HuD-specific T-cell responses were observed. These results are at variance with the detection of HuD-specific CD4<sup>+</sup> T-cell proliferative responses in PBMC of Hu-PNS patients by Benyahia et&#x000a0;al. [<xref ref-type="bibr" rid="CR1">1</xref>]. This discrepancy may be explained by differences in read-out (i.e., 3-day lymphocyte proliferation in Benyahia&#x02019;s study [<xref ref-type="bibr" rid="CR1">1</xref>] vs. overnight cytokine production in ours) and the use of recombinant HuD protein [<xref ref-type="bibr" rid="CR1">1</xref>] versus a protein-spanning 15-mer peptide pool (this manuscript).</p><p>We then studied responses to HLA class-I binding HuD peptides that were previously selected [<xref ref-type="bibr" rid="CR20">20</xref>]. Using the same experimental setup and HuD 9-mer peptides, Rousseau et&#x000a0;al. [<xref ref-type="bibr" rid="CR20">20</xref>] reported HuD-specific T-cell reactivity in 7/10 Hu-PNS patients and in 3/10 HC [<xref ref-type="bibr" rid="CR20">20</xref>]. In that small study a positive response was defined as an experimental value &#x02265;2 times above background. With that criterion, 3 PNS, 2 SCLC and 4 HC would have been classified as HuD T-cell responders in our study. However, using that cut-off we would also have detected T-cell reactivity in individuals whose Class-I HLA molecules did not have the appropriate binding motifs (data not shown). Therefore, we used more stringent cut-off levels resulting in a negative outcome. As most patients in both studies had progressive neurological disease and were tested shortly after start of symptoms and prior to therapy, differences between the study populations do not explain this discrepancy.</p><p>Finally, we could not detect HuD-specific circulating CD8<sup>+</sup> T cells using Class-I HLA multimers with the same fine specificities as defined by Rousseau et&#x000a0;al. [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>The absence of detectable circulating HuD-specific CD8<sup>+ </sup>T cells may not be surprising. In a PCR-based study, Plonquet et&#x000a0;al. [<xref ref-type="bibr" rid="CR18">18</xref>] detected the same T-cell clone in neoplastic and nervous tissues, but not in blood. This finding suggests that T cells involved in the pathogenesis of Hu-PNS circulate in concentrations below detection level. An immune response taking place in the central nervous system parenchyma may deplete the circulating pool of CD8<sup>+</sup> T cells with that specificity [<xref ref-type="bibr" rid="CR23">23</xref>]. Furthermore, vaccination studies in melanoma patients demonstrate that clinically effective anti-tumour immune responses may occur despite low levels of melanoma-specific cytotoxic T cells, i.e., below the detection limit of multimer-based assays [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p>In conclusion, we were unable to detect HuD-specific T cells in a large cohort of Hu-PNS patients and controls. However, two of our three assays were designed for the detection of CD8<sup>+</sup> T cells only. The IgG<sub>1</sub> isotype predominance of serum Hu antibodies in Hu-PNS indicates a T-helper response to the Hu antigen [<xref ref-type="bibr" rid="CR13">13</xref>]. Therefore, further studies are warranted that focus on the detection of circulating HuD-specific CD4<sup>+ </sup>T cells. In this context, regulatory CD4<sup>+</sup> T cells&#x02014;which down regulate immune responses towards auto-antigens and tumour-antigens&#x02014;are of interest. Although the numbers of regulatory T cells are increased in cancer patients [<xref ref-type="bibr" rid="CR26">26</xref>] and in PNS patients [<xref ref-type="bibr" rid="CR8">8</xref>] (de Beukelaar et al. unpublished data) their (possibly impaired) function in PNS remains to be studied. Finally, examination of the antigen-specificity of T cells in affected tissues may shed further light on the role of HuD-specific T cells in the pathogenesis of Hu-PNS.</p></sec></body><back><ack><p>This study was supported by a &#x0201c;Revolving Fund&#x0201d; grant from Erasmus MC (Rotterdam, The Netherlands).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Benyahia</surname><given-names>B</given-names></name><name><surname>Liblau</surname><given-names>R</given-names></name><name><surname>Merle-Beral</surname><given-names>H</given-names></name><name><surname>Tourani</surname><given-names>JM</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Delattre</surname><given-names>JY</given-names></name></person-group><article-title>Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies</article-title><source>Ann Neurol</source><year>1999</year><volume>45</volume><fpage>162</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199902)45:2&#x0003c;162::AID-ANA5&#x0003e;3.0.CO;2-R</pub-id></citation><citation citation-type="display-unstructured">Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY (1999) Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol 45:162&#x02013;167 <pub-id pub-id-type="pmid">9989617</pub-id></citation></ref><ref id="CR2"><label>2.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernal</surname><given-names>F</given-names></name><name><surname>Graus</surname><given-names>F</given-names></name><name><surname>Pifarre</surname><given-names>A</given-names></name><name><surname>Saiz</surname><given-names>A</given-names></name><name><surname>Benyahia</surname><given-names>B</given-names></name><name><surname>Ribalta</surname><given-names>T</given-names></name></person-group><article-title>Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis</article-title><source>Acta Neuropathol (Berl)</source><year>2002</year><volume>103</volume><fpage>509</fpage><lpage>515</lpage><pub-id pub-id-type="doi">10.1007/s00401-001-0498-0</pub-id></citation><citation citation-type="display-unstructured">Bernal F, Graus F, Pifarre A, Saiz A, Benyahia B, Ribalta T (2002) Immunohistochemical analysis of anti-Hu-associated paraneoplastic encephalomyelitis. Acta Neuropathol (Berl) 103:509&#x02013;515 <pub-id pub-id-type="pmid">11935268</pub-id></citation></ref><ref id="CR3"><label>3.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Carpentier</surname><given-names>AF</given-names></name><name><surname>Rosenfeld</surname><given-names>MR</given-names></name><name><surname>Delattre</surname><given-names>JY</given-names></name><name><surname>Whalen</surname><given-names>RG</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name></person-group><article-title>DNA vaccination with HuD inhibits growth of a neuroblastoma in mice</article-title><source>Clin Cancer Res</source><year>1998</year><volume>4</volume><fpage>2819</fpage><lpage>2824</lpage></citation><citation citation-type="display-unstructured">Carpentier AF, Rosenfeld MR, Delattre JY, Whalen RG, Posner JB, Dalmau J (1998) DNA vaccination with HuD inhibits growth of a neuroblastoma in mice. Clin Cancer Res 4:2819&#x02013;2824 <pub-id pub-id-type="pmid">9829748</pub-id></citation></ref><ref id="CR4"><label>4.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coulie</surname><given-names>PG</given-names></name><name><surname>Karanikas</surname><given-names>V</given-names></name><name><surname>Colau</surname><given-names>D</given-names></name><name><surname>Lurquin</surname><given-names>C</given-names></name><name><surname>Landry</surname><given-names>C</given-names></name><name><surname>Marchand</surname><given-names>M</given-names></name><etal/></person-group><article-title>A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3</article-title><source>Proc Natl Acad Sci USA</source><year>2001</year><volume>98</volume><fpage>10290</fpage><lpage>10295</lpage><pub-id pub-id-type="doi">10.1073/pnas.161260098</pub-id></citation><citation citation-type="display-unstructured">Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M et al. (2001) A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci USA 98:10290&#x02013;10295 <pub-id pub-id-type="pmid">11517302</pub-id></citation></ref><ref id="CR5"><label>5.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darnell</surname><given-names>RB</given-names></name></person-group><article-title>Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain</article-title><source>Proc Natl Acad Sci USA</source><year>1996</year><volume>93</volume><fpage>4529</fpage><lpage>4536</lpage><pub-id pub-id-type="doi">10.1073/pnas.93.10.4529</pub-id></citation><citation citation-type="display-unstructured">Darnell RB (1996) Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci USA 93:4529&#x02013;4536 <pub-id pub-id-type="pmid">8643438</pub-id></citation></ref><ref id="CR6"><label>6.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darnell</surname><given-names>RB</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name></person-group><article-title>Observing the invisible: successful tumor immunity in humans</article-title><source>Nat Immunol</source><year>2003</year><volume>4</volume><fpage>201</fpage><pub-id pub-id-type="doi">10.1038/ni0303-201</pub-id></citation><citation citation-type="display-unstructured">Darnell RB, Posner JB (2003) Observing the invisible: successful tumor immunity in humans. Nat Immunol 4:201 <pub-id pub-id-type="pmid">12605223</pub-id></citation></ref><ref id="CR7"><label>7.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Darnell</surname><given-names>RB</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name></person-group><article-title>Paraneoplastic syndromes involving the nervous system</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>1543</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1056/NEJMra023009</pub-id></citation><citation citation-type="display-unstructured">Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543&#x02013;1554 <pub-id pub-id-type="pmid">14561798</pub-id></citation></ref><ref id="CR8"><label>8.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Andres</surname><given-names>C</given-names></name><name><surname>Esquivel</surname><given-names>A</given-names></name><name><surname>Villoria</surname><given-names>JG</given-names></name><name><surname>Graus</surname><given-names>F</given-names></name><name><surname>Sanchez-Ramon</surname><given-names>S</given-names></name></person-group><article-title>Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2006</year><volume>77</volume><fpage>562</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2005.073379</pub-id></citation><citation citation-type="display-unstructured">de Andres C, Esquivel A, de Villoria JG, Graus F, Sanchez-Ramon S (2006) Unusual magnetic resonance imaging and cerebrospinal fluid findings in paraneoplastic cerebellar degeneration: a sequential study. J Neurol Neurosurg Psychiatry 77:562&#x02013;563 <pub-id pub-id-type="pmid">16543544</pub-id></citation></ref><ref id="CR9"><label>9.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beukelaar</surname><given-names>JW</given-names></name><name><surname>Sillevis Smitt</surname><given-names>PA</given-names></name></person-group><article-title>Managing paraneoplastic neurological disorders</article-title><source>Oncologist</source><year>2006</year><volume>11</volume><fpage>292</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.11-3-292</pub-id></citation><citation citation-type="display-unstructured">de Beukelaar JW, Sillevis Smitt PA (2006) Managing paraneoplastic neurological disorders. Oncologist 11:292&#x02013;305 <pub-id pub-id-type="pmid">16549814</pub-id></citation></ref><ref id="CR10"><label>10.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waal</surname><given-names>L</given-names></name><name><surname>Yuksel</surname><given-names>S</given-names></name><name><surname>Brandenburg</surname><given-names>AH</given-names></name><name><surname>Langedijk</surname><given-names>JP</given-names></name><name><surname>Sintnicolaas</surname><given-names>K</given-names></name><name><surname>Verjans</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein</article-title><source>J Virol</source><year>2004</year><volume>78</volume><fpage>1775</fpage><lpage>1781</lpage><pub-id pub-id-type="doi">10.1128/JVI.78.4.1775-1781.2004</pub-id></citation><citation citation-type="display-unstructured">de Waal L, Yuksel S, Brandenburg AH, Langedijk JP, Sintnicolaas K, Verjans GM, et al (2004) Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein. J Virol 78:1775&#x02013;1781 <pub-id pub-id-type="pmid">14747542</pub-id></citation></ref><ref id="CR11"><label>11.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gratama</surname><given-names>JW</given-names></name><name><surname>Esser</surname><given-names>JW</given-names></name><name><surname>Lamers</surname><given-names>CH</given-names></name><name><surname>Tournay</surname><given-names>C</given-names></name><name><surname>Lowenberg</surname><given-names>B</given-names></name><name><surname>Bolhuis</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection</article-title><source>Blood</source><year>2001</year><volume>98</volume><fpage>1358</fpage><lpage>1364</lpage><pub-id pub-id-type="doi">10.1182/blood.V98.5.1358</pub-id></citation><citation citation-type="display-unstructured">Gratama JW, van Esser JW, Lamers CH, Tournay C, Lowenberg B, Bolhuis RL et al (2001) Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 98:1358&#x02013;1364 <pub-id pub-id-type="pmid">11520783</pub-id></citation></ref><ref id="CR12"><label>12.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Graus</surname><given-names>F</given-names></name><name><surname>Delattre</surname><given-names>JY</given-names></name><name><surname>Antoine</surname><given-names>JC</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Giometto</surname><given-names>B</given-names></name><name><surname>Grisold</surname><given-names>W</given-names></name><etal/></person-group><article-title>Recommended diagnostic criteria for paraneoplastic neurological syndromes</article-title><source>J Neurol Neurosurg Psychiatry</source><year>2004</year><volume>75</volume><fpage>1135</fpage><lpage>1140</lpage><pub-id pub-id-type="doi">10.1136/jnnp.2003.034447</pub-id></citation><citation citation-type="display-unstructured">Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W et al (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135&#x02013;1140 <pub-id pub-id-type="pmid">15258215</pub-id></citation></ref><ref id="CR13"><label>13.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jean</surname><given-names>WC</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Ho</surname><given-names>A</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name></person-group><article-title>Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis</article-title><source>Neurology</source><year>1994</year><volume>44</volume><fpage>140</fpage><lpage>147</lpage></citation><citation citation-type="display-unstructured">Jean WC, Dalmau J, Ho A, Posner JB (1994) Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu-associated paraneoplastic encephalomyelitis. Neurology 44:140&#x02013;147 <pub-id pub-id-type="pmid">8290049</pub-id></citation></ref><ref id="CR14"><label>14.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kern</surname><given-names>F</given-names></name><name><surname>Faulhaber</surname><given-names>N</given-names></name><name><surname>Frommel</surname><given-names>C</given-names></name><name><surname>Khatamzas</surname><given-names>E</given-names></name><name><surname>Prosch</surname><given-names>S</given-names></name><name><surname>Schonemann</surname><given-names>C</given-names></name><etal/></person-group><article-title>Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides</article-title><source>Eur J Immunol</source><year>2000</year><volume>30</volume><fpage>1676</fpage><lpage>1682</lpage><pub-id pub-id-type="doi">10.1002/1521-4141(200006)30:6&#x0003c;1676::AID-IMMU1676&#x0003e;3.0.CO;2-V</pub-id></citation><citation citation-type="display-unstructured">Kern F, Faulhaber N, Frommel C, Khatamzas E, Prosch S, Schonemann C et al. (2000) Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 30:1676&#x02013;1682 <pub-id pub-id-type="pmid">10898504</pub-id></citation></ref><ref id="CR15"><label>15.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>PH</given-names></name></person-group><article-title>Differential expression of the neuroendocrine genes Hel-N1 and HuD in small-cell lung carcinoma: evidence for down-regulation of HuD in the variant phenotype</article-title><source>Int J Cancer</source><year>1997</year><volume>74</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-0215(19970822)74:4&#x0003c;378::AID-IJC3&#x0003e;3.0.CO;2-S</pub-id></citation><citation citation-type="display-unstructured">King PH (1997) Differential expression of the neuroendocrine genes Hel-N1 and HuD in small-cell lung carcinoma: evidence for down-regulation of HuD in the variant phenotype. Int J Cancer 74:378&#x02013;382 <pub-id pub-id-type="pmid">9291425</pub-id></citation></ref><ref id="CR16"><label>16.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Knutson</surname><given-names>KL</given-names></name><name><surname>dela Rosa</surname><given-names>C</given-names></name><name><surname>Disis</surname><given-names>ML</given-names></name></person-group><article-title>Laboratory analysis of T-cell immunity</article-title><source>Front Biosci</source><year>2006</year><volume>11</volume><fpage>1932</fpage><lpage>1944</lpage><pub-id pub-id-type="doi">10.2741/1936</pub-id></citation><citation citation-type="display-unstructured">Knutson KL, dela Rosa C, Disis ML (2006) Laboratory analysis of T-cell immunity. Front Biosci 11:1932&#x02013;1944 <pub-id pub-id-type="pmid">16368569</pub-id></citation></ref><ref id="CR17"><label>17.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Manley</surname><given-names>GT</given-names></name><name><surname>Smitt</surname><given-names>PS</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name></person-group><article-title>Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites</article-title><source>Ann Neurol</source><year>1995</year><volume>38</volume><fpage>102</fpage><lpage>110</lpage><pub-id pub-id-type="doi">10.1002/ana.410380117</pub-id></citation><citation citation-type="display-unstructured">Manley GT, Smitt PS, Dalmau J, Posner JB (1995) Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 38:102&#x02013;110 <pub-id pub-id-type="pmid">7541976</pub-id></citation></ref><ref id="CR18"><label>18.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plonquet</surname><given-names>A</given-names></name><name><surname>Gherardi</surname><given-names>RK</given-names></name><name><surname>Creange</surname><given-names>A</given-names></name><name><surname>AntoineJC</surname></name><name><surname>Benyahia</surname><given-names>B</given-names></name><name><surname>Grisold</surname><given-names>W</given-names></name><etal/></person-group><article-title>Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome</article-title><source>J Neuroimmunol</source><year>2002</year><volume>122</volume><fpage>100</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(01)00452-0</pub-id></citation><citation citation-type="display-unstructured">Plonquet A, Gherardi RK, Creange A, AntoineJC, Benyahia B, Grisold W et al (2002) Oligoclonal T-cells in blood and target tissues of patients with anti-Hu syndrome. J Neuroimmunol 122:100&#x02013;105 <pub-id pub-id-type="pmid">11777548</pub-id></citation></ref><ref id="CR19"><label>19.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Plonquet</surname><given-names>A</given-names></name><name><surname>Garcia-Pons</surname><given-names>F</given-names></name><name><surname>Fernandez</surname><given-names>E</given-names></name><name><surname>Philippe</surname><given-names>C</given-names></name><name><surname>Marquet</surname><given-names>J</given-names></name><name><surname>Rouard</surname><given-names>H</given-names></name><etal/></person-group><article-title>Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human</article-title><source>J Neuroimmunol</source><year>2003</year><volume>142</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1016/S0165-5728(03)00269-8</pub-id></citation><citation citation-type="display-unstructured">Plonquet A, Garcia-Pons F, Fernandez E, Philippe C, Marquet J, Rouard H et al. (2003) Peptides derived from the onconeural HuD protein can elicit cytotoxic responses in HHD mouse and human. J Neuroimmunol 142:93&#x02013;100 <pub-id pub-id-type="pmid">14512168</pub-id></citation></ref><ref id="CR20"><label>20.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rousseau</surname><given-names>A</given-names></name><name><surname>Benyahia</surname><given-names>B</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Connan</surname><given-names>F</given-names></name><name><surname>Guillet</surname><given-names>JG</given-names></name><name><surname>Delattre</surname><given-names>JY</given-names></name><etal/></person-group><article-title>T cell response to Hu-D peptides in patients with anti-Hu syndrome</article-title><source>J Neurooncol</source><year>2005</year><volume>71</volume><fpage>231</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1007/s11060-004-1723-1</pub-id></citation><citation citation-type="display-unstructured">Rousseau A, Benyahia B, Dalmau J, Connan F, Guillet JG, Delattre JY et al (2005) T cell response to Hu-D peptides in patients with anti-Hu syndrome. J Neurooncol 71:231&#x02013;236 <pub-id pub-id-type="pmid">15735910</pub-id></citation></ref><ref id="CR21"><label>21.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sillevis Smitt</surname><given-names>P</given-names></name><name><surname>Grefkens</surname><given-names>J</given-names></name><name><surname>Leeuw</surname><given-names>B</given-names></name><name><surname>Bent</surname><given-names>M</given-names></name><name><surname>Putten</surname><given-names>W</given-names></name><name><surname>Hooijkaas</surname><given-names>H</given-names></name><etal/></person-group><article-title>Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy</article-title><source>J Neurol</source><year>2002</year><volume>249</volume><fpage>745</fpage><lpage>753</lpage><pub-id pub-id-type="doi">10.1007/s00415-002-0706-4</pub-id></citation><citation citation-type="display-unstructured">Sillevis Smitt P, Grefkens J, de Leeuw B, van den Bent M, van Putten W, Hooijkaas H et al (2002) Survival and outcome in 73 anti-Hu positive patients with paraneoplastic encephalomyelitis/sensory neuronopathy. J Neurol 249:745&#x02013;753 <pub-id pub-id-type="pmid">12111309</pub-id></citation></ref><ref id="CR22"><label>22.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sillevis Smitt</surname><given-names>PA</given-names></name><name><surname>Manley</surname><given-names>GT</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name></person-group><article-title>Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice</article-title><source>Neurology</source><year>1995</year><volume>45</volume><fpage>1873</fpage><lpage>1878</lpage></citation><citation citation-type="display-unstructured">Sillevis Smitt PA, Manley GT, Posner JB (1995) Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 45:1873&#x02013;1878 <pub-id pub-id-type="pmid">7477985</pub-id></citation></ref><ref id="CR23"><label>23.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stevenson</surname><given-names>PG</given-names></name><name><surname>Bangham</surname><given-names>CR</given-names></name><name><surname>Hawke</surname><given-names>S</given-names></name></person-group><article-title>Recruitment, activation and proliferation of CD8+ memory T cells in an immunoprivileged site</article-title><source>Eur J Immunol</source><year>1997</year><volume>27</volume><fpage>3259</fpage><lpage>3268</lpage><pub-id pub-id-type="doi">10.1002/eji.1830271225</pub-id></citation><citation citation-type="display-unstructured">Stevenson PG, Bangham CR, Hawke S (1997) Recruitment, activation and proliferation of CD8+ memory T cells in an immunoprivileged site. Eur J Immunol 27:3259&#x02013;3268 <pub-id pub-id-type="pmid">9464814</pub-id></citation></ref><ref id="CR24"><label>24.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Maruyama</surname><given-names>Y</given-names></name><name><surname>Sugie</surname><given-names>M</given-names></name><name><surname>Motizuki</surname><given-names>H</given-names></name><name><surname>Kamakura</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name></person-group><article-title>Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome</article-title><source>J Neurol Sci</source><year>2002</year><volume>201</volume><fpage>9</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/S0022-510X(02)00157-0</pub-id></citation><citation citation-type="display-unstructured">Tanaka M, Maruyama Y, Sugie M, Motizuki H, Kamakura K, Tanaka K (2002) Cytotoxic T cell activity against peptides of Hu protein in anti-Hu syndrome. J Neurol Sci 201:9&#x02013;12 <pub-id pub-id-type="pmid">12163187</pub-id></citation></ref><ref id="CR25"><label>25.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voltz</surname><given-names>R</given-names></name><name><surname>Dalmau</surname><given-names>J</given-names></name><name><surname>Posner</surname><given-names>JB</given-names></name><name><surname>Rosenfeld</surname><given-names>MR</given-names></name></person-group><article-title>T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>1146</fpage><lpage>1150</lpage></citation><citation citation-type="display-unstructured">Voltz R, Dalmau J, Posner JB, Rosenfeld MR (1998) T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. Neurology 51:1146&#x02013;1150 <pub-id pub-id-type="pmid">9781545</pub-id></citation></ref><ref id="CR26"><label>26.</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>AM</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Steurer</surname><given-names>M</given-names></name><name><surname>Gastl</surname><given-names>G</given-names></name><name><surname>Gunsilius</surname><given-names>E</given-names></name><name><surname>Grubeck-Loebenstein</surname><given-names>B</given-names></name></person-group><article-title>Increase of regulatory T cells in the peripheral blood of cancer patients</article-title><source>Clin Cancer Res</source><year>2003</year><volume>9</volume><fpage>606</fpage><lpage>612</lpage></citation><citation citation-type="display-unstructured">Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B (2003) Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9:606&#x02013;612 <pub-id pub-id-type="pmid">12576425</pub-id></citation></ref></ref-list></back></article>


